NEW YORK, NY / ACCESS Newswire / December 6, 2025 / If you suffered a loss on your Stride, Inc. (NYSE:LRN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/stride-inc-lawsuit-submission-form-3?prid=179773&wire=1&utm_campaign=2 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call […]

NEW YORK, NY / ACCESS Newswire / December 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Bath & Body Works, Inc. ("Bath & Body Works, Inc.") (NYSE:BBWI) concerning possible violations of federal securities laws. On November 20, 2025, BBWI published results for the third quarter of fiscal 2025

NEW YORK, NY / ACCESS Newswire / December 6, 2025 / If you suffered a loss on your WPP plc (NYSE:WPP) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/wpp-plc-lawsuit-submission-form?prid=179765&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / December 6, 2025 / If you suffered a loss on your CarMax, Inc. (NYSE:KMX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/carmax-inc-lawsuit-submission-form?prid=179764&wire=1&utm_campaign=4 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

— Company named “Best Financially Managed Semiconductor Company (Achieving Greater than $1 Billion in Annual Sales)” and “Outstanding Asia-Pacific Semiconductor Company” simultaneously — Accelerates recovery from market downturn leveraging world-class HBM leadership; Global management performance recognized — Reflects company's technology leadership and customer-centric execution — SK Chairman Chey Tae-won emphasizes: “Technological competitiveness must remain unwavering

Washington, DC, Dec. 06, 2025 (GLOBE NEWSWIRE) — ThinkCareBelieve's Week 46 Article: https://thinkcarebelieve.blog/2025/12/06/week-46-america-shining-brightly/ The 2025 National Security Strategy Article: https://thinkcarebelieve.blog/2025/12/06/the-2025-national-security-strategy-2/ America's Weekly Golden Chronicle: https://thinkcarebelieve.blog/2025/12/01/americas-weekly-golden-chronicle-list/ Washington, D.C. – ThinkCareBelieve today released a comprehensive review of Week 46 of the second Trump Administration, describing it as a period of remarkable intensity paired with calm resolve, marked

ThinkCareBelieve: Week 46 America Shining Brightly Week 46 of the Trump 2.0 Administration GlobeNewswire December 06, 2025 Washington, DC, Dec. 06, 2025 (GLOBE NEWSWIRE) — ThinkCareBelieve's Week 46 Article: https://thinkcarebelieve.blog/2025/12/06/week-46-america-shining-brightly/ The 2025 National Security Strategy Article: https://thinkcarebelieve.blog/2025/12/06/the-2025-national-security-strategy-2/ America's Weekly Golden Chronicle: https://thinkcarebelieve.blog/2025/12/01/americas-weekly-golden-chronicle-list/ Washington, D.C. – ThinkCareBelieve today released a comprehensive review of Week 46 of

NEW YORK CITY, NY / ACCESS Newswire / December 6, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM) and certain officers.�� The class action, filed in the United States District Court for the Southern District of New York, and docketed under 25-cv-08912,

NEW YORK CITY, NY / ACCESS Newswire / December 6, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against MoonLake Immunotherapeutics ("Moonlake" or the "Company") (NASDAQ:MLTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

NEW YORK CITY, NY / ACCESS Newswire / December 6, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ:TLX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are